May 7, 2024

CGM initiation and A1c outcomes for Pubs committee

May Publication Committee Slides Final

Publication Committee Meeting May 7, 2024

Attendees: Shideh Majidi, Ann Mungmode, Holly Hardison, Nicole Rioles, Osagie Ebekozien, Liz Mann, Priya Prahalad, Emily Breidbart, Ruth Weinstock, Carla Demeterco-Berggren, Grace Nelson, , Grace Nelson, Kalis Akturk, Manu Kamboj, Margaret Zupa, Francesco Vendrame, Monica Bianco, Alissa Roberts, Laura Jacobsen, Naomi Fogel, Jenise Wong, Todd Seeherunvong, Stephanie Crossen, Sarah Lyons

Agenda:

• New Co-Chair Introductions
  • Stephanie Crossen from UC Davis and Halis Akturk from Barbara Davis\
  • Thank you to Shideh Majidi and Shivani Agarwal for their leadership, co-chairing the committee in 2022-2024
• Publications updates
  • 17 Phase 5 Publications
  • 11 Phase 4 Publications
  • 1 Phase 3 Publication
  • 4 Phase 2 Publications
  • 7 Phase 1 Publications
• Upcoming Conferences
  • T1DX-QI Faculty ADA 2024 Breakfast RSVP
    • Please join us for the Faculty Breakfast at the 2024 ADA Scientific Sessions in Orlando, FL. Breakfast will be held Sunday June 23rd, from 6:30-9 am EST RSVP
  • Learning Session Call for Abstracts
    • 11/11 QI Collaborative conference. Happening over one day. Attendees can plan to fly into Chicago Sunday evening, 11/10.
    • ADEPT (Equity conference) Happening 11/11-11/12 in Chicago, following the Learning Collaborative conference.
    • Learning Session conference abstracts are now open: Please submit your abstracts using this link.
    • Links to both conferences contain FAQ documents to help answer your questions.
  • Upcoming Publication Discussion
    • CGM Initiation within 6 months of diagnosis associated with lower A1c at 3 years in youth with T1D but disparities continue to exist
      • Suggestion to clarify if median A1C in table is at baseline or after 36 months
      • Consider changing bar graph of CGM initiation by race/ethnicity to cluster bars by race/ethnicity (so that %s add up to 100 in each group, and can see likely timing of CGM adoption for each racial/ethnic group)
      • Presenting change in A1c (from baseline) would help For line graph showing A1c change after diagnosis, would be interesting to break down into separate lines for those using AID systems and those just on CGM (if able), especially since your study period overlaps with when widespread AID systems like Control IQ first came out.
      • Title Change to disparities persist
      • Figure 1, separate into a 4 part figure a,b,c,d
      • Coverage by state?
      • Hispanic to be separated to Spanish speaking and non-Spanish speaking
    • T2D Data Update
      • Consider changing age range because 65+ is Medicare
      • Insulin vs non-insulin
      • What level of detail do we have on non-insulin medication use?
        • Details by class
      • Tease out patient who had initial insulin, before being put on new type
      • time from medication rx to medication start?
      • And would look at CGM effects by race/ethnicity within T2D Complications in T2D more prevalent in peds and adults
      • Screening disorders

Link to Recording:

https://us02web.zoom.us/rec/share/gTncKxDGxoHP_u4DCqPWqhhgxQG36nG6ajTch3iINq-OHYNrgX-5lX3FfHgOhnC-.zBglXkTARVIJtkT1?startTime=1715108458000

Passcode: Z0R%wS#y